{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:24:37Z","timestamp":1791228277234,"version":"4.1.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2011,5,2]],"date-time":"2011-05-02T00:00:00Z","timestamp":1304294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p>The objective of this study was to determine the shortest period of time necessary to detect histologic evidence of estrous cycle disruption in Sprague-Dawley rats treated for up to 28 days with the aromatase inhibitor exemestane at 1,000 mg\/kg. Rats were evaluated on day 5, 8, 15, or 29. Vaginal mucification, uterine and cervical epithelial atrophy, uterine luminal epithelial vacuolation, decreased uterine granulocytes, and hypertrophy\/hyperplasia of mammary ducts and alveoli were noted by day 5 and persisted throughout the study. From day 8 to day 29, absence of recent basophilic corpora lutea, increased atresia of antral follicles, interstitial cell hyperplasia, and increased luteinized follicles were present in the ovaries of treated rats. Vaginal smears detected persistent diestrus, confirming estrous cycle disruption between days 5 and 8. Ovary and uterine weights were largely unaffected. Serum hormone levels were not useful due to the study design employed. Other effects of exemestane included decreased adrenal weights and decreased cell size in both the adrenal zona fasciculata and the pituitary pars distalis. While early histologic changes were evident on day 5, only after 8 days of treatment were findings considered sufficient to clearly identify exemestane-induced estrous cycle disruption using microscopy alone.<\/jats:p>","DOI":"10.1177\/0192623311402220","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T20:12:48Z","timestamp":1304453568000},"page":"589-605","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Histologic and Cytologic Detection of Endocrine and Reproductive Tract Effects of Exemestane in Female Rats Treated for up to Twenty-eight Days"],"prefix":"10.1177","volume":"39","author":[{"given":"Michael L.","family":"Mirsky","sequence":"first","affiliation":[{"name":"Pfizer Global Research and Development, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Sivaraman","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Drug Safety Evaluation, New Brunswick, New Jersey, USA"},{"name":"Although now at the new address indicated, L. Sivaraman was affiliated with Pfizer during the conduct of this study."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Houle","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Potter","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Chapin","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg D.","family":"Cappon","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,5,2]]},"reference":[{"key":"bibr1-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.12.028"},{"key":"bibr2-0192623311402220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002040100214","volume":"75","author":"Andrews P.","year":"2001","journal-title":"Arch Toxicol"},{"key":"bibr3-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0312"},{"key":"bibr4-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2006.04.006"},{"key":"bibr5-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1002\/ar.1091540112"},{"key":"bibr6-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2008.291"},{"key":"bibr7-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1210\/endo-24-5-723"},{"key":"bibr8-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(82)90187-X"},{"key":"bibr9-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1006\/faat.1993.1003"},{"key":"bibr10-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012515400-0\/50034-8"},{"key":"bibr11-0192623311402220","first-page":"665","volume":"8","author":"Cohen M. H.","year":"2002","journal-title":"Clin Cancer Res"},{"key":"bibr12-0192623311402220","author":"Creasy D.","year":"2008","journal-title":"Organization of Economic Cooperation and Development"},{"key":"bibr13-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1080\/019262301301418874"},{"key":"bibr14-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(87)91523-8"},{"key":"bibr15-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0740341"},{"key":"bibr16-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(96)00064-7"},{"key":"bibr17-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-6-3-371"},{"key":"bibr18-0192623311402220","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research (FDA CDER) (1997). Femara. NDA # 20-726. Drug Approval Package, Pharmacology Review. Retrieved August 18, 2010, from www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/020726_femara_toc.cfm"},{"key":"bibr19-0192623311402220","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research (FDA CDER) (1999). Aromasin. NDA # 20-753. Drug Approval Package, Pharmacology Review. Retrieved August 18, 2010, from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/20-753_Aromasin.cfm"},{"key":"bibr20-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012515400-0\/50048-8"},{"key":"bibr21-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20106"},{"key":"bibr22-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1975.147"},{"key":"bibr23-0192623311402220","first-page":"137","volume":"15","author":"Houjou T.","year":"1993","journal-title":"Clin Ther"},{"key":"bibr24-0192623311402220","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2009). Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2). Retrieved March 17, 2011, from http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/M3_R2\/Step4\/M3_R2__Guideline.pdf"},{"key":"bibr25-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2003.10.005"},{"key":"bibr26-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.05.002"},{"key":"bibr27-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1210\/endo-30-1-93"},{"key":"bibr28-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20120"},{"key":"bibr29-0192623311402220","first-page":"110","volume":"76","author":"Ljungkvist I.","year":"1971","journal-title":"Acta Soc Med Ups"},{"key":"bibr30-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1080\/01926230601156260"},{"key":"bibr31-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-0168"},{"key":"bibr32-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026491221687"},{"key":"bibr33-0192623311402220","doi-asserted-by":"publisher","DOI":"10.2131\/jts.22.1"},{"key":"bibr34-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1320091"},{"key":"bibr35-0192623311402220","unstructured":"Organization of Economic Cooperation and Development (OECD) (2007). Draft Updated Test Guideline 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents. Retrieved August 17, 2010, from www.oecd.org\/dataoecd\/22\/27\/39791889.pdf"},{"key":"bibr36-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1080\/01926230500343902"},{"key":"bibr37-0192623311402220","doi-asserted-by":"publisher","DOI":"10.2131\/jts.34.S1"},{"key":"bibr38-0192623311402220","doi-asserted-by":"publisher","DOI":"10.2131\/jts.22.5_427"},{"key":"bibr39-0192623311402220","doi-asserted-by":"publisher","DOI":"10.2131\/jts.34.S91"},{"key":"bibr40-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1210\/endo-96-1-219"},{"key":"bibr41-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1210\/endo.139.2.5762"},{"key":"bibr42-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20060"},{"key":"bibr43-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-9384(01)00487-5"},{"key":"bibr44-0192623311402220","first-page":"SP43","volume":"34","author":"Tsujioka S.","year":"2009","journal-title":"Toxicol Pathol"},{"key":"bibr45-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2003.12.018"},{"key":"bibr46-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1177\/0192623308315665"},{"key":"bibr47-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1002\/ar.1090660404"},{"key":"bibr48-0192623311402220","first-page":"192","volume":"45","author":"Yano S.","year":"1996","journal-title":"Arzneim Forsch"},{"key":"bibr49-0192623311402220","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90313-3"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623311402220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0192623311402220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623311402220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:32:45Z","timestamp":1777653165000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0192623311402220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,2]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1177\/0192623311402220"],"URL":"https:\/\/doi.org\/10.1177\/0192623311402220","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,2]]}}}